1Kroiss M, Sherman E, Wirth LJ, et al. Durable efficacy of selpercatinib in patients (pts) with medullary thyroid cancer (MTC): update of the LIBRETTO-001 trial. Presented at: the European Society for Medical Oncology (ESMO); Paris, France; September 9-13, 2022.
2Datos de archivo, Eli Lilly and Company y/o uno de sus subsidiarios.
3Andreev-Drakhlin A, Cabanillas M, Amini B, Subbiah V. Systemic and CNS activity of selective RET inhibition with selpercatinib (LOXO-292) in a patient with RET-mutant medullary thyroid cancer with extensive CNS metastases. JCO Precis Oncol. 2020;4:1302-1306. https://dx.doi.org/10.1200/PO.20.00096
4Sherman E, Wirth L, Shah M, et al. Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: a LIBRETTO-001 update. Poster presented at: 57th Annual Meeting of the American Society of Clinical Oncology (ASCO Virtual); June 4-8, 2021. Accessed November 9, 2022. https://assets.ctfassets.net/mpejy6umgthp/3Akm5uCVsGOJEwrbsmT1Zh/2b3be4e81531356578012b689702141a/SELPT1_ASCO2021_Sherman.pdf
5Drilon A, Subbiah V, Gautschi O, et al. Selpercatinib in patients with RET fusion–positive non–small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol. 2022. Published online September 19, 2022. https//doi.org/10.1200/jco.22.00393
6Retsevmo [Ficha Técnica]. Eli Lilly Nederland B.V., Países Bajos.
7Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383(9):825-835. https://dx.doi.org/10.1056/NEJMoa2005651
8Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion–positive non–small-cell lung cancer. N Engl J Med. 2020;383(9):813-824. https://dx.doi.org/10.1056/NEJMoa2005653
9Phase 1/2 study of LOXO-292 in patients with advanced solid tumors, RET fusion-positive solid tumors, and medullary thyroid cancer (LIBRETTO-001). ClinicalTrials.gov identifier: NCT03157128. Updated October 12, 2022. Accessed October 12, 2022. https://www.clinicaltrials.gov/ct2/show/NCT03157128